Losartan

"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

Descriptor ID	D019808
MeSH Number(s)	D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
Concept/Terms	Losartan Losartan 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol DuP-753 DuP-753 DuP 753 DuP753 MK-954 MK-954 MK 954 MK954 Cozaar Cozaar Losartan Potassium Losartan Potassium Potassium, Losartan Losartan Monopotassium Salt Monopotassium Salt, Losartan Salt, Losartan Monopotassium

Below are MeSH descriptors whose meaning is more general than "Losartan".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Biphenyl Compounds [D02.455.426.559.389.185]
Losartan [D02.455.426.559.389.185.475]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Losartan [D03.383.129.308.507]
Tetrazoles [D03.383.129.617]
Losartan [D03.383.129.617.467]

Below are MeSH descriptors whose meaning is related to "Losartan".

Below are MeSH descriptors whose meaning is more specific than "Losartan".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.

Bar chart showing 24 publications over 17 distinct years, with a maximum of 3 publications in 1997 and 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
1997	1	2	3
1999	1	0	1
2001	1	1	2
2002	1	0	1
2003	1	0	1
2004	0	2	2
2005	1	0	1
2006	0	1	1
2007	1	0	1
2008	3	0	3
2009	0	1	1
2010	1	0	1
2014	0	1	1
2015	1	0	1
2017	1	0	1
2018	0	1	1

Below are the most recent publications written about "Losartan" by people in Profiles.

Delaitre C, Boisbrun M, Acherar S, Dias A, Kleinclauss A, Achard M, Colin M, Nguyen TM, Humbert N, Chmeis K, Martinez KL, Gilles N, Robin P, Lecat S, Dupuis F. Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, ?-Arrestin-Biased Agonists, and Antagonists. J Med Chem. 2024 Nov 28; 67(22):20275-20297.

View in: PubMed
Nu?ez RE, Javadov S, Escobales N. Critical role of angiotensin II type 2 receptors in the control of mitochondrial and cardiac function in angiotensin II-preconditioned rat hearts. Pflugers Arch. 2018 09; 470(9):1391-1403.

View in: PubMed
Gerena Y, Lozada JG, Collazo BJ, M?ndez-?lvarez J, M?ndez-Estrada J, De Mello WC. Losartan counteracts the effects of cardiomyocyte swelling on glucose uptake and insulin receptor substrate-1 levels. Peptides. 2017 Oct; 96:38-43.

View in: PubMed
Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Am J Hematol. 2017 Sep; 92(9):E520-E528.

View in: PubMed
Javadov S, Escobales N. The Role of SIRT3 in Mediating Cardioprotective Effects of RAS Inhibition on Cardiac Ischemia-Reperfusion. J Pharm Pharm Sci. 2015; 18(3):547-50.

View in: PubMed
Hern?ndez JS, Barreto-Torres G, Kuznetsov AV, Khuchua Z, Javadov S. Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria. J Cell Mol Med. 2014 Apr; 18(4):709-20.

View in: PubMed
De Mello WC. Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within. Mol Cell Biochem. 2011 Dec; 358(1-2):309-15.

View in: PubMed
Xu X, Zhao W, Wan W, Ji LL, Powers AS, Erikson JM, Zhang JQ. Exercise training combined with angiotensin II receptor blockade reduces oxidative stress after myocardial infarction in rats. Exp Physiol. 2010 Oct; 95(10):1008-15.

View in: PubMed
De Mello WC, Gerena Y. Prolonged exposure of cardiac cells to renin plus angiotensinogen reduces intracellular renin in the failing heart. On the role of angiotensin II-AT1 complex internalization. Regul Pept. 2009 Jun 05; 155(1-3):139-44.

View in: PubMed
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.

View in: PubMed

People

Explore

Similar Concepts

Top Journals